Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne, Switzerland.
Clin Cancer Res. 2015 Jul 15;21(14):3108-12. doi: 10.1158/1078-0432.CCR-14-2261. Epub 2015 May 12.
Tumor-infiltrating myeloid-derived suppressor cells (MDSC) are a heterogeneous and immunosuppressive cell subset that blocks the proliferation and the activity of both T and natural killer (NK) cells and promotes tumor vasculogenesis and progression. Recent evidences demonstrate that the recruitment of MDSCs in tumors also blocks senescence induced by chemotherapy promoting chemoresistance. Hence, the need of novel therapeutic approaches that can efficiently target MDSC recruitment and function in cancer. Among them, novel combinatorial treatments of chemotherapy and immunotherapy or treatments that induce depletion of MDSCs in peripheral sites should be taken in consideration.
肿瘤浸润髓系来源的抑制性细胞（MDSC）是一种异质性的、免疫抑制性细胞亚群，可阻断 T 细胞和自然杀伤（NK）细胞的增殖和活性，并促进肿瘤血管生成和进展。最近的证据表明，MDSC 在肿瘤中的募集也阻止了化疗诱导的衰老，从而促进了化疗耐药性。因此，需要新的治疗方法，能够有效地针对癌症中 MDSC 的募集和功能。其中，化疗和免疫治疗的新组合治疗或诱导外周部位 MDSC 耗竭的治疗应被考虑。
